Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

3518 ARTÍCULOS , VIENDO DEL 1636 AL 1650

Cold Atmospheric Plasmas: A Novel and Promising Way to Treat Neurological Diseases

Xiong Z.

Trends Biotechnol. 2018 Jun;36(6):582-583. doi: 10.1016/j.tibtech.2018.04.003. Epub 2018 Apr 21.

ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease

Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W, Ward M, Friesenhahn M, Rabe C, Brunstein F, Quartino A, Honigberg LA, Fuji RN, Clayton D, Mortensen D, Ho C, Paul R.

Neurology. 2018 May 22;90(21):e1889-e1897. doi: 10.1212/WNL.0000000000005550. Epub 2018 Apr 25.

Technological Solutions for Older People with Alzheimer's Disease: Review

Maresova P, Tomsone S, Lameski P, Madureira J, Mendes A, Zdravevski E, Chorbev I, Trajkovik V, Ellen M, Rodile K.

Curr Alzheimer Res. 2018;15(10):975-983. doi: 10.2174/1567205015666180427124547.

Targeting Insulin for Alzheimer's Disease: Mechanisms, Status and Potential Directions

Lee JH, Jahrling JB, Denner L, Dineley KT.

J Alzheimers Dis. 2018;64(s1):S427-S453. doi: 10.3233/JAD-179923.

Effectiveness of Anti-Dementia Drugs in Extremely Severe Alzheimer's Disease: A 12-Week, Multicenter, Randomized, Single-Blind Study

Hong YJ, Choi SH, Jeong JH, Park KW, Na HR.

J Alzheimers Dis. 2018;63(3):1035-1044. doi: 10.3233/JAD-180159.

Exercise Intervention Associated with Cognitive Improvement in Alzheimer's Disease

Cui MY, Lin Y, Sheng JY, Zhang X, Cui RJ.

Neural Plast. 2018 Mar 11;2018:9234105. doi: 10.1155/2018/9234105. eCollection 2018.

Issues in Geriatric Care: Alzheimer Disease

Kemle K, Ackermann RJ.

FP Essent. 2018 May;468:26-34.

A double-blind placebo-controlled cross-over clinical trial of DONepezil In Posterior cortical atrophy due to underlying Alzheimer's Disease: DONIPAD study

Ridha BH, Crutch S, Cutler D, Frost C, Knight W, Barker S, Epie N, Warrington EK, Kukkastenvehmas R, Douglas J, Rossor MN.

Alzheimers Res Ther. 2018 May 1;10(1):44. doi: 10.1186/s13195-018-0363-1.

Monotherapy Is Good Enough for Patients with Mild-to-Moderate Alzheimer's Disease: A Network Meta-analysis of 76 Randomized Controlled Trials

Tsoi KK, Chan JY, Chan FC, Hirai HW, Kwok TC, Wong SY.

Clin Pharmacol Ther. 2019 Jan;105(1):121-130. doi: 10.1002/cpt.1104. Epub 2018 Jun 19.

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease

Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Harper Mozley L, Vandenberghe R, Mo Y, Michelson D.

N Engl J Med. 2018 May 3;378(18):1691-1703. doi: 10.1056/NEJMoa1706441.

Drug development for Alzheimer's disease: review

Lao K, Ji N, Zhang X, Qiao W, Tang Z, Gou X.

J Drug Target. 2019 Feb;27(2):164-173. doi: 10.1080/1061186X.2018.1474361. Epub 2018 Jun 20.

Short-Term Response to Cholinesterase Inhibitors in Alzheimer's Disease Delays Time to Nursing Home Placement

Wattmo C, Londos E, Minthon L.

Curr Alzheimer Res. 2018;15(10):905-916. doi: 10.2174/1567205015666180507105326.

Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region

Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Hamano N, Li SD, Chougule M, Shoyele SA, Gupta U, Ajazuddin, Alexander A.

Expert Opin Drug Deliv. 2018 Jun;15(6):589-617. doi: 10.1080/17425247.2018.1471058. Epub 2018 May 17.

The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer's disease

Jazvinšćak Jembrek M, Slade N, Hof PR, Šimić G.

Prog Neurobiol. 2018 Sep;168:104-127. doi: 10.1016/j.pneurobio.2018.05.001. Epub 2018 May 4.

Benzofuran and Indole: Promising Scaffolds for Drug Development in Alzheimer's Disease

Goyal D, Kaur A, Goyal B.

ChemMedChem. 2018 Jul 6;13(13):1275-1299. doi: 10.1002/cmdc.201800156. Epub 2018 Jun 19.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias